Prosecution Insights
Prosecution Insights
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (20%) |
| §112 only | 3 (60%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
| RAHMANI, NILOOFAR | 1 | 77.5% | -3.1% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.5% |
| NOLAN, JASON MICHAEL | 1 | 66.3% | -28.0% |
| BAEK, BONG-SOOK | 1 | 41.7% | +69.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18620978 | SALTS AND SOLID FORMS OF A COMPOUND HAVING GLP-1 AGONIST ACTIVITY | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044196 | HETEROCYCLIC GLP-1 AGONISTS | BAEK, BONG-SOOK | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044196 | HETEROCYCLIC GLP-1 AGONISTS | BAEK, BONG-SOOK | 12d |
| 18837146 | HETEROCYCLIC GLP-1 AGONISTS | CHANDRAKUMAR, NIZAL S | — |
| 18620978 | SALTS AND SOLID FORMS OF A COMPOUND HAVING GLP-1 AGONIST ACTIVITY | WILLIS, DOUGLAS M | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1623 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837146 | HETEROCYCLIC GLP-1 AGONISTS | CHANDRAKUMAR, NIZAL S | — | §112 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18759609 | HETEROCYCLIC AGONISTS | RAHMANI, NILOOFAR | — | §112 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18620978 | SALTS AND SOLID FORMS OF A COMPOUND HAVING GLP-1 AGONIST ACTIVITY | WILLIS, DOUGLAS M | 1624 | §112Other | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18248858 | HETEROCYCLIC GLP-1 AGONISTS | NOLAN, JASON MICHAEL | 1623 | §102 | Non-Final OA | — | Pending | Apr 12, 2023 |
| 18044196 | HETEROCYCLIC GLP-1 AGONISTS | BAEK, BONG-SOOK | 1611 | §103§112 | Non-Final OA | 12d | Pending | Mar 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial